Close Menu

cancer of unknown primary

The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.

Researchers re-examined whole-genome and whole-transcriptome sequencing TCGA studies from 33 cancer types and found unique microbial signatures.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.

The FDA has granted accelerated approval to Rozlytrek as a treatment for adult and adolescent patients with NTRK fusion-positive cancers.

Rutgers researchers have developed a point-of-care tool that can rapidly assess the sensitivity of tumor cells to cancer drugs without staining or labeling.

The company said the decrease was partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards.

The firm said revenues from its precision oncology business increased 98 percent in Q4, driven by higher testing volume and increased revenue per test.

The investment bank said it is encouraged by the company's strong pipeline and position among its competitors but sees further upside for its stock.

The company said it will use the proceeds to develop new liquid biopsy tests to predict drug response in cancer patients.

Pages